Proteasome inhibitors: Their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells

BMC Pharmacology

Volumn 4, Issue , 2004, Pages

  Levine, Lawrence ^a  

^a BRANDEIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DACTINOMYCIN; EPOXOMICIN; LACTACYSTIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTACYCLIN; PROTEASOME INHIBITOR; ACETYLCYSTEINE; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; DRUG DERIVATIVE; LEUPEPTIN; OLIGOPEPTIDE;

ANIMAL CELL; APOPTOSIS; ARACHIDONIC ACID METABOLISM; ARTICLE; BASAL CELL; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; ENZYME SYNTHESIS; GLIA CELL; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CULTURE; NONHUMAN; OSSIFICATION; RAT; ANIMAL; BREAST TUMOR; CELL LINE; CELL STRAIN HT29; CYTOLOGY; DRUG EFFECT; GLIA; INNERVATION; LIVER; METABOLISM; TUMOR CELL LINE;

ACETYLCYSTEINE; ANIMALS; ARACHIDONIC ACID; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; HT29 CELLS; HUMANS; LEUPEPTINS; LIVER; NEUROGLIA; OLIGOPEPTIDES; PROTEASOME INHIBITORS; RATS;

EID: 12944268754     PISSN: 14712210     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2210-4-15     Document Type: Article

References (32)

1. Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8: 39-758.
2. Mitchell BS: The proteasome - an emerging therapeutic target in cancer. N Engl J Med 2003, 348:2597-2598.
3. Adams J: Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003, 8:307-315.
4. Hanada M, Sugawara K, Kaneta K, Toda S, Nishiyama Y, Tomita K, Yamamoto H, Konishi M, Oki T: Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo 1992, 45:1746-1752.
5. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 1999, 96: 0403-10408.
6. Ostrowska H, Wojcik C, Omura S, Worowski K: Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem Biophys Res Commun 1997, 234:729-732.
7. Mellgren RL: Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome. J Biol Chem 1997, 272:29899-29903.
8. Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, Ploegh H: Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A 1997, 94: 629-6634.
9. Bromme D, Klaus JL, Okamoto K, Rasnick D, Palmer JT: Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem J 1996, 315:85-89.
10. Levine L: Proteolysis negatively regulates agonist-stimulated arachidonic acid metabolism. Cell Signal 1998, 10:653-659.
11. Levine L: Lactacystin stimulates arachidonic acid metabolism in rat liver cells: effects of cell density on arachidonic acid release, PGI2 production and cyclooxygenase activity. Prostaglandins Leukot Essent Fatty Acids 2000, 63:371-375.
12. Rockwell P, Yuan H, Magnusson R, Figueiredo-Pereira ME: Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys 2000, 374:325-333.
13. Rigas A, Levine L: Arachidonic acid metabolism by rat liver cells (the C-9 cell line). J Pharmacol Exp Ther 1984, 231:230-235.
14. Levine L: Tamoxifen and the raloxifene analog LY117018: their effects on arachidonic acid release from cell in culture and on prostaglandin I2 production by rat liver cells. BMC Cancer 2004.
15. Smith WL: The eicosanoids and their biochemical mechanisms of action. Biochem J 1989, 259:315-324.
16. Edidin M: The state of lipid rafts: from model membranes to cells. Annu Rev Biophys Biomol Struct 2003, 32:257-279.
17. Levine L: Does the release of arachidonic acid from cells play a role in cancer chemoprevention? FASEB J 2003, 17: 00-802.
18. Levine L: Tamoxifen stimulates arachidonic acid release from rat liver cells by an estrogen receptor-independent, nongenomic mechanism. BMC Cancer 2003, 3:24.
19. Levine L: Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells. Lipids Health Dis 2003, 2:1.
20. Levine L: Nuclear receptor agonists stimulate release of arachidonic acid from rat liver cells. Prostaglandins Leukot Essent Fatty Acids 2002, 67:453-459.
21. Diaz BL, Arm JP: Phospholipase A(2). Prostaglandins Leukot Essent Fatty Acids 2003, 69:87-97.
22. Praml C, Amler LC, Dihlmann S, Finke LH, Schlag P, Schwab M: Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa. Oncogene 1998, 17:2009-2012.
23. Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, Dove WF, Lander ES: Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nature Genetics 1997, 17:88-91.
24. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM: The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995, 81:957-966.
25. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR: Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003, 111:1771-1782.
26. Subbaramaiah K, Dannenberg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003, 24:96-102.
27. Jordan VC, Morrow M: Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 1999, 20:253-278.
28. Brower V: Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst 2003, 95:844-846.
29. Brash AR.: Arachidonic acid as a bioactive molecule. J Clin Invest 2001, 107:1339-1345.
30. Laye JP, Gill JH: Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discov Today 2003, 8:710-716.
31. Levine L: Stimulated release of arachidonic acid from rat liver cells by celecoxib and indomethacin. Prostaglandins Leukot Essent Fatty Acids 2001, 65:31-35.
32. Levine L: Measurement of arachidonic acid metabolites by radioimmunoassay. Manual of Clinical Laboratory Immunology. 3rd edition. Edited by: Rose NR, Friedman H, Fahey JL. Washington DC: American Society for Microbiology; 1986:685-691.